The study drew on the German Stroke Registry–Endovascular Treatment (GSR-ET), a prospective, multicenter registry spanning 25 comprehensive stroke centers across Germany. Between June 2015 and December 2023, more than 18,000 patients were screened, and after excluding those with extracranial carotid occlusions, pre-stroke disability, or missing key clinical data, 5,448 patients treated with mechanical thrombectomy for anterior circulation strokes formed the analytical cohort. The mean age was 71.2 years, 48 percent were women, and the median stroke severity on admission, measured by the National Institutes of Health Stroke Scale (NIHSS), was 13. The researchers stratified patients into nine subgroups based on admission NIHSS (0–10, 11–15, or ≥16) and the Alberta Stroke Program Early CT Score (ASPECTS), a ten-point measure of early infarct signs on CT imaging (10, 8–9, or ≤7).

This dual stratification was designed to capture what neurointerventionalists call clinical-core mismatch. The concept is elegant: a patient whose neurological deficit is dramatically worse than the visible extent of infarction likely has a large penumbra, a zone of struggling but still salvageable brain tissue, whereas a patient whose symptoms are mild relative to a large established infarct has less to gain from reopening the vessel. The DAWN and DEFUSE-3 trials famously demonstrated that patients with pronounced mismatch benefit from thrombectomy even in extended time windows of up to 24 and 16 hours, respectively. But those trials used sophisticated perfusion imaging and volumetric core measurements. The new study instead used the readily available NIHSS and ASPECTS scores as a clinical surrogate, testing whether the same pattern holds in the messy reality of routine practice.

The results were striking. Reperfusion success was graded using the modified Thrombolysis in Cerebral Infarction (mTICI) scale: 650 patients achieved minimal or no reperfusion (mTICI 0–2a), 1,873 achieved partial reperfusion (mTICI 2b), and 2,925 achieved complete recanalization (mTICI 3). Unadjusted outcomes followed a steep gradient: only 20 percent of patients with failed reperfusion achieved functional independence, defined as a modified Rankin Scale (mRS) score of 0 to 2 at 90 days, compared with 46 percent after partial reperfusion and 54 percent after complete recanalization. Mortality at 90 days told the same story in reverse, at 39 percent, 20 percent, and 17 percent respectively. Symptomatic intracranial hemorrhage, a feared procedural complication, occurred in 5 percent of failed reperfusion cases but only 2 percent of complete recanalizations.

Because patients who achieve full recanalization may differ systematically from those who do not, the researchers applied inverse-probability-weighted regression adjustment (IPWRA), a double-robust statistical technique that controls for confounders such as age, sex, comorbidities, baseline NIHSS and ASPECTS, intravenous thrombolysis, and the number of retrieval attempts. The adjusted estimates confirmed the pattern: 25 percent good outcomes after mTICI 0–2a, 46 percent after mTICI 2b, and 52 percent after mTICI 3, with adjusted mean mRS scores of 4.0, 3.0, and 2.7 respectively. Crucially, significant benefit from successful reperfusion was observed in every one of the nine NIHSS-ASPECTS subgroups, including patients with large established infarcts and those with only mild symptoms.

The size of that benefit, however, varied dramatically. The clearest beneficiaries were patients with high clinical-core mismatch, particularly those with a perfect ASPECTS of 10 and severe deficits (NIHSS ≥16). In this group, only 9 percent of patients with failed reperfusion achieved functional independence, compared with 47 percent after complete recanalization, an absolute difference of 38 percentage points. Patients with moderate deficits (NIHSS 11–15) and ASPECTS 10 showed comparable gains. At the opposite extreme, patients with severe deficits and extensive infarct signs (NIHSS ≥16, ASPECTS ≤7) saw a much smaller but still significant benefit, with good outcomes rising from 12 percent to 23 percent, an absolute difference of 11 percentage points. The exploratory mRS shift analysis reinforced the pattern, showing the largest disability reduction, nearly two full mRS points, in the ASPECTS 10 and NIHSS 11–15 subgroup.

One of the most clinically consequential findings concerned the difference between near-complete and complete reperfusion. Pushing from mTICI 2b to mTICI 3 often requires additional retrieval attempts, each carrying a risk of vessel perforation, dissection, or distal clot migration. The data showed that the extra benefit of full recanalization was concentrated in high-mismatch patients: in the NIHSS ≥16, ASPECTS 10 subgroup, complete recanalization lifted good outcomes from 32 percent to 47 percent, a 15-point gain. But in patients with large infarcts (NIHSS ≥16, ASPECTS ≤7), outcomes were essentially identical after mTICI 2b and mTICI 3, both around 20 percent. The authors suggest that in selected low-mismatch cases, accepting mTICI 2b as an adequate procedural endpoint may be a pragmatic choice that avoids unnecessary procedural risk.

The findings also complicate the emerging picture from randomized trials. Recent studies such as SELECT2, ANGEL-ASPECT, RESCUE-Japan LIMIT, and TENSION demonstrated that even patients with large established infarcts benefit from thrombectomy, expanding treatment beyond the classic mismatch paradigm. Meanwhile, a post-hoc analysis of ANGEL-ASPECT failed to show benefit in patients stratified by clinical-radiological mismatch, and recent trials in distal medium vessel occlusions have questioned whether mismatch concepts translate uniformly across vascular territories. The new registry data reconcile some of this tension: mismatch profiles appear to modify the size of the treatment effect rather than determine whether treatment helps at all. In other words, clinical-core mismatch should inform expectations and procedural goals, not serve as a rigid gatekeeper for eligibility.

The authors are careful to note important limitations. Roughly 70 percent of screened patients were excluded in the complete-case analysis because of missing variables, a substantial selection process that may bias effect estimates and limit generalizability to unselected populations. Patients with pre-stroke disability were excluded, local investigators rather than a central core lab graded ASPECTS and mTICI, and unmeasured factors such as collateral circulation, infarct location, and time from onset to imaging could not be fully accounted for. The use of linearized mRS scores in exploratory analyses also assumes equal spacing between scale points, an assumption that may not fully hold. These caveats mean the findings in mild stroke and low-ASPECTS groups should be considered exploratory, even as the high-mismatch results align closely with prior randomized evidence.

Looking forward, the study points toward a more individualized era of stroke treatment. Rather than fixed subgroup thresholds, the authors argue that outcome effects across ASPECTS likely follow a continuous gradient, and future selection tools may integrate advanced imaging biomarkers such as net water uptake, a quantitative measure of early brain swelling, to estimate each patient’s likely benefit from reperfusion. For now, the message for clinicians is nuanced but actionable: successful reperfusion helps virtually every patient profile, but the magnitude of benefit is greatest when a severe deficit signals a large salvageable penumbra, and the pursuit of complete recanalization matters most precisely in those patients. In resource-limited settings where every thrombectomy counts, that distinction could help ensure the right patients receive the most aggressive endovascular effort.

Subject of Research: Reperfusion-dependent outcomes after endovascular thrombectomy for acute ischemic stroke, stratified by NIHSS-ASPECTS clinical-core mismatch

Article Title: Reperfusion‐Dependent Outcomes After Endovascular Thrombectomy Stratified by NIHSS‐ASPECTS Clinical‐Core Mismatch

Article References: Schlicht, F., Meyer, L., Broocks, G., Bechstein, M., Thaler, C., Heitkamp, C., Winkelmeier, L., Geest, V., Heitkamp, A., Jungnitz, M., Peter, G., Meucci, L., Faizy, T., Nawabi, J., Brekenfeld, C., Flottmann, F., Schell, M., Hadjilaou, A., Hanning, U., … German Stroke Registry Endovascular Treatment (2026). Reperfusion‐Dependent Outcomes After Endovascular Thrombectomy Stratified by NIHSS ‐ ASPECTS Clinical‐Core Mismatch. Annals of Clinical and Translational Neurology, 13(9), 1807-1816. https://doi.org/10.1002/acn3.70358

Image Credits: AI Generated

DOI: 10.1002/acn3.70358

Keywords: mechanical thrombectomy, acute ischemic stroke, reperfusion, clinical-core mismatch, NIHSS, ASPECTS, mTICI, functional outcome, German Stroke Registry, large vessel occlusion, penumbra, neurointervention

Mechanical thrombectomy, in which physicians thread catheters through blood vessels to physically remove a clot, is the established standard of care for acute ischemic stroke caused by a large vessel occlusion. Intravenous thrombolysis with the drug alteplase is recommended as first-line therapy within four and a half hours of symptom onset, and beyond that window when perfusion imaging shows salvageable brain tissue. When both treatments are used, the combination is known as bridging therapy. Yet the practice remains debated, because intravenous thrombolysis carries a risk of hemorrhage, and well-designed trials comparing direct thrombectomy with bridging therapy have produced mixed results. A recent Cochrane systematic review pooling six randomized controlled trials found no evidence of a difference in functional outcome, mortality, or intracranial hemorrhage between the two strategies, and its authors called for research into time- and person-specific factors that might determine who benefits from the intravenous drug.

Researchers at University Hospital Carl Gustav Carus in Dresden suspected that one such factor might be the biological composition of the clot itself. Clots removed from patients with large vessel occlusion vary considerably in their proportions of fibrin and red blood cells, and these differences fall largely along etiological lines. Clots of cardiac origin, which form when the heart’s rhythm falters and debris travels to the brain, tend to be rich in fibrin and platelets. Clots arising from atherosclerotic disease in the neck or brain arteries tend to be red blood cell rich. Fibrin-rich clots are denser, create more friction against vessel walls, and are known to be less sensitive to thrombolytic drugs, which work by infiltrating the clot and thinning its fibrin fibers. Red blood cell rich clots, with their more loosely packed fibrin networks, allow greater drug penetration and dissolve more readily.

To test whether these biological differences translate into different treatment outcomes, the team conducted a post hoc analysis of their prospective registry of consecutive thrombectomy patients treated between January 2017 and January 2023. The cohort included 798 adults who underwent thrombectomy for anterior circulation large vessel occlusion, either at the Dresden center directly or after transfer from one of thirteen telestroke network spokes or eight partner primary stroke centers in eastern Saxony. Just over half the patients were women, the median age was 77 years, and the median baseline stroke severity on the National Institutes of Health Stroke Scale was 15. Nearly half of the patients, 395 in total, received intravenous alteplase before thrombectomy; no other thrombolytic agents were used during the study period. Stroke etiology was classified according to the TOAST criteria by senior stroke consultants and validated through a secondary central review of all medical records.

The primary outcome was the time from groin puncture to successful angiographic reperfusion, quantified using the modified Thrombolysis in Cerebral Infarction score, with successful reperfusion defined as a score of 2b or higher. The researchers used stratified Cox proportional hazards regression, adjusting for age, baseline stroke severity, tandem occlusions, carotid T occlusions, occlusion site, and distal thrombus migration—a shift of the clot from a proximal to a more distal arterial segment that occurred before any endovascular maneuver. Overall, successful reperfusion was achieved in 85.2 percent of patients, and cardioembolic stroke accounted for 58.9 percent of cases.

The results split cleanly along etiological lines. Among the 330 patients with non-cardioembolic stroke, bridging intravenous thrombolysis was independently associated with a roughly 40 percent higher hazard of achieving successful reperfusion at any point during the procedure, with an adjusted hazard ratio of 1.40. This effect grew stronger in sensitivity analyses: when patients with stroke of undetermined etiology were excluded, the adjusted hazard ratio rose to 2.06, and a sub-analysis restricted to patients with large artery atherosclerotic stroke reproduced the benefit. Consistent with this, patients with atherosclerotic stroke who received the intravenous drug required about 36 percent fewer aspiration attempts during thrombectomy, an effect measured with a negative binomial regression that accounted for age, initial CT severity score, and occlusion site.

Among the 468 patients with cardioembolic stroke, however, the picture was entirely different. Intravenous thrombolysis alone showed no measurable effect on time to reperfusion, with an adjusted hazard ratio of 1.13 that did not reach statistical significance. More troubling, when the clot migrated distally after thrombolysis and before the procedure—a phenomenon observed in 9.7 percent of cardioembolic patients who received the drug versus 0.8 percent of those who did not—the likelihood of successful reperfusion at any given time point dropped by approximately 43 percent, with an adjusted hazard ratio of 0.57. The researchers propose that when thrombolysis fails to soften a fibrin-rich cardiac clot, it may instead promote its displacement into smaller, more distal arterial segments where thrombectomy is technically harder and less effective, a concern underscored by two recent negative randomized trials of thrombectomy for distal vessel occlusions.

The study also quantified the clinical stakes of procedural speed. Each additional 10 minutes of groin-to-recanalization time increased the odds of a worse functional outcome on the modified Rankin scale at 90 days by 8.6 percent, an association that remained robust after adjustment for patient characteristics, stroke features, interventional parameters, and metabolic markers. In other words, a treatment that accelerates reperfusion in one stroke subtype and delays it in another could meaningfully shift outcomes for individual patients, even if population-level averages obscure the difference.

The mechanistic story fits a growing body of evidence. Analyses of the MR CLEAN Registry biobank and other prospective thrombus studies have shown that cardioembolic clots contain a higher proportion of fibrin and platelets, while atherosclerotic clots are predominantly red blood cell rich. Fibrin-rich thrombi demand more recanalization attempts and yield lower reperfusion rates, and laboratory work suggests they are less susceptible to thrombolytic agents because their fibrin is densely packed. The multicenter RESTORE Registry found that clots retrieved in earlier thrombectomy passes had higher red blood cell content, while later passes yielded fibrin-rich material. Beyond simple histology, molecular analyses have identified neutrophil extracellular traps as structural components that stabilize the fibrin network and may contribute to thrombolysis resistance—raising the possibility that partial clot destabilization without effective lysis could promote distal embolization and increase procedural complexity.

The Dresden team is careful to note the limitations of their work. The data come from a regional network registry, histological characterization of retrieved clots was not available, and the subgroup of cardioembolic patients with distal thrombus migration was small, leaving room for residual confounding despite robust statistical adjustment. Cryptogenic stroke, moreover, is a highly heterogeneous category that may mask diverse underlying mechanisms. Still, the consistency of the etiological differences across all multivariable models, and their reproduction in the atherosclerotic sub-analysis, suggest a robust finding. If confirmed in larger studies, the results could help clinicians move beyond a one-size-fits-all approach to bridging therapy, reserving intravenous thrombolysis for the patients whose clots are most likely to yield to it—and sparing others a treatment that may do more harm than good.

Subject of Research: Effect of intravenous thrombolysis before thrombectomy on reperfusion outcomes in cardioembolic versus non-cardioembolic acute ischemic stroke

Article Title: IV Thrombolysis Facilitates Interventional Reperfusion in Non‐Cardioembolic but Not Cardioembolic Stroke

Article References: Sedghi, A., Kaiser, D. P. O., Arndt, M., Diel, N. J., Simon, E., Polanski, W. H., Puetz, V., Huttner, H. B., & Siepmann, T. (2026). IV Thrombolysis Facilitates Interventional Reperfusion in Non‐Cardioembolic but Not Cardioembolic Stroke. Annals of Clinical and Translational Neurology, 13(9), 1893-1902. https://doi.org/10.1002/acn3.70370

Image Credits: AI Generated

DOI: 10.1002/acn3.70370

Keywords: stroke, thrombectomy, intravenous thrombolysis, large vessel occlusion, cardioembolic stroke, clot composition, reperfusion, alteplase, TOAST classification, distal thrombus migration, fibrin-rich thrombi, bridging therapy

The technology’s lineage traces back to the first-generation Merci retriever, a corkscrew-like device approved in the mid-2000s that proved mechanical clot removal in the brain was feasible but achieved only modest recanalization rates. The decisive turning point came with self-expanding stent retrievers, notably Solitaire and Trevo, which are compressed inside a microcatheter, navigated through the vasculature to the clot, and then unsheathed so the nitinol mesh expands and integrates with the thrombus. Unlike a static stent left in place, these retrievers engage the clot mechanically across its full length, allowing the operator to pull the entire construct into a guide catheter. Randomized trials published in 2015, including MR CLEAN, ESCAPE, EXTEND-IA, SWIFT PRIME, and REVASCAT, together demonstrated overwhelming benefit of endovascular thrombectomy over medical therapy alone, reshaping international guidelines almost overnight and establishing first-generation stent retrievers as the anchor of modern stroke intervention.

The technical principle behind the second-generation devices is deceptively simple: radial force from the expanding mesh compresses the clot against the vessel wall while individual struts penetrate the thrombus, creating a mechanical interlock. In practice, the interaction is governed by a complex interplay of clot composition, device geometry, and vessel size. Ischemic stroke thrombi vary enormously, from soft, red-cell-rich emboli shed from the heart to hard, fibrin-rich clots loaded with platelets and von Willebrand factor that resist mechanical integration. Histological analyses cited in the review show that fibrin-dense outer shells and platelet-rich regions correlate with failed retrieval and poorer revascularization outcomes. This biological heterogeneity has pushed engineers toward devices with segmented designs, larger mesh cells, and specialized capture zones. Multi-zone platforms such as NeVa incorporate discrete drop zones with tightly spaced struts designed to trap organized clots, while radially adjustable retrievers such as Tigertriever allow the operator to expand the device progressively until it matches the vessel diameter, an advantage in both oversized proximal vessels and narrow distal branches.

Device development has also converged on integrated retrieval-and-protection concepts. EmboTrap-class retrievers feature distal capture baskets intended to intercept fragments that would otherwise migrate downstream and cause new infarcts, a complication known as distal embolization. registries such as ARISE II and the global EXCELLENT registry for the EMBOTRAP device have reported high first-pass reperfusion rates with these hybrid designs. First-pass effect, meaning complete reperfusion achieved in a single retrieval attempt, has emerged as a key performance metric because each additional pass increases procedural time, trauma to the endothelium, and the risk of hemorrhagic transformation. Recent generation devices such as Solitaire X have demonstrated significantly improved first-pass success compared with their predecessors, and tip-design studies confirm that the shape and stiffness of the retriever’s distal end materially influence whether fragments escape during withdrawal.

In parallel with hardware evolution, procedural technique has advanced into highly choreographed combinations. The most influential refinement is the pairing of stent retrievers with large-bore aspiration catheters positioned at the face of the clot, a strategy variously branded as Solumbra, SAVE, or ARTS. Aspiration continuously extracts clot fragments dislodged by the retriever, reducing the shower of emboli that would otherwise travel into healthy territory. Balloon guide catheters add a second layer of protection by temporarily arresting antegrade flow in the parent artery, creating a stagnant zone from which debris can be vacuumed rather than washed distally. The randomized PROTECT-MT trial from China showed that balloon guide catheters significantly improve excellent reperfusion rates, validating what in-vitro flow studies had long predicted. For refractory occlusions, operators increasingly deploy double stent retrievers simultaneously, doubling the mechanical interface with the clot, and recent bench studies plus the randomized TWIN2WIN trial support this bail-out strategy, although cumulative vessel wall injury remains a documented concern in animal models.

The clinical indications for thrombectomy have expanded dramatically alongside the devices themselves. Landmark trials including DAWN and DEFUSE 3 extended the treatment window from six hours to twenty-four hours in patients selected by advanced perfusion imaging, demonstrating that brain tissue can remain salvageable long after symptom onset when collateral circulation is robust. More recently, attention has turned to posterior circulation strokes caused by basilar artery occlusion, which are uniformly devastating without treatment; trials such as ATTENTION and BAOCHE provided the first randomized evidence supporting endovascular therapy in this territory. Equally consequential are the new studies in large infarct cores, including SELECT2, ANGEL-ASPECT, and RESCUE-Japan LIMIT, which overturned the long-held exclusion of patients with extensive established damage and showed net functional benefit from thrombectomy even in these high-risk presentations.

The most recent frontier involves medium and distal vessel occlusions, blocks in arteries one to three millimeters in diameter that were historically managed with medication because standard devices were too bulky. Purpose-built low-profile retrievers, including 3-millimeter variants of Solitaire X and Trevo and the adjustable Tigertriever 13, have enabled operators to reach these small vessels, and a wave of randomized trials in 2025 and 2026, including DISTALS, DISTAL, and DISCOUNT, has begun to establish benefit under imaging-guided selection. The review emphasizes that territory-specific engineering, from smaller delivery profiles to softer, more flexible distal architectures, is now the dominant axis of device innovation, with hybrid devices such as Aperio and specialized platforms for cerebral venous sinus thrombosis broadening the field further.

Materials science is contributing a quieter but potentially transformative layer of progress. Nitinol remains the workhorse alloy because its superelasticity allows dense crimping and atraumatic self-expansion, but its poor radiographic visibility complicates positioning, prompting coatings and design changes that enhance fluoroscopic contrast. Surface engineering aims to reduce thrombogenicity and endothelial damage, with heparin-based hydrogel coatings, endothelium-mimicking bioactive layers, and nanostructured oxide films under investigation. More provocative are clot-adhesive coatings that deliberately bind to fibrin, effectively welding the retriever to resistant thrombi, and micro-patterned surfaces that increase contact area. In a striking departure from conventional designs, milli-spinner thrombectomy, reported in Nature in 2025, uses a rotating, tangle-forming structure to compress and extract clots regardless of composition, hinting that the retrieval paradigm itself may not be permanent.

Looking forward, the review identifies thrombus characterization as the bridge between biology and device choice. Radiomic analysis of clot appearance on imaging, combined with biomarkers of clot composition, could soon allow operators to predict before the first pass whether a given occlusion will yield to a standard retriever or demand an adjustable device, dual-stent technique, or direct aspiration. Personalized device selection of this kind would attack the core unresolved problems: fibrin-rich resistant thrombi, embolic complications, vascular injury from repeated passes, and the limited high-level evidence supporting many of the newest devices, which have largely been validated in registries rather than randomized trials. The authors argue that ongoing integration of engineering innovation with rigorous clinical data will support increasingly individualized and safer thrombectomy strategies, and with stroke remaining a leading cause of disability globally, even incremental gains in first-pass success translate into meaningful reductions in death and dependence. The stent retriever, born from a simple wire mesh, continues to evolve into a precision instrument tailored to the specific clot, vessel, and patient standing between a stroke and recovery.

The stakes of these technical refinements are best understood against the sheer scale of the disease. Global burden analyses cited in the review estimate that stroke affected well over a hundred million people worldwide in recent years, and large vessel occlusions contribute disproportionately to death and dependence because the entire territory of a major cerebral artery is threatened within minutes of onset. Intravenous thrombolysis, the other pillar of acute reperfusion therapy, dissolves clot biochemically but achieves recanalization in only a minority of large vessel occlusions and carries a risk of arterial reocclusion, which is why mechanical retrieval became indispensable.

The review also situates current practice within the 2026 American Heart Association and American Stroke Association guideline for early management of acute ischemic stroke, reflecting how trial evidence is rapidly codified into standards of care. Beyond the procedure itself, the authors note that reperfusion initiates a second wave of injury, including blood-brain barrier breakdown and neuroinflammation, meaning that restoring flow is necessary but not always sufficient for good functional recovery. This biological reality underscores why procedural metrics such as first-pass success and reduced embolization matter clinically, and why the field increasingly views mechanical thrombectomy not as an isolated engineering problem but as one component of a broader effort spanning imaging selection, device design, and post-reperfusion neuroprotection.

Subject of Research: Technological advances and clinical applications of stent retrievers in endovascular thrombectomy for acute ischemic stroke.

Article Title: Stent retrievers for acute ischemic stroke: technological advances, clinical applications, and future perspectives

Article References: Xie, Z., Wang, Z., Fu, P., Shi, Z., Zhuang, Z., Wang, H., Xiang, Y., Yin, X., & Chen, Z. (2026). Stent retrievers for acute ischemic stroke: technological advances, clinical applications, and future perspectives. Journal of Neurology, 273(10), Article 590. https://doi.org/10.1007/s00415-026-14126-z

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14126-z

Keywords: acute ischemic stroke, stent retriever, mechanical thrombectomy, large vessel occlusion, endovascular treatment, first-pass reperfusion, nitinol, distal embolization, balloon guide catheter, medium vessel occlusion, thrombus composition, reperfusion